Premium
Effect of cyclophosphamide on leukocytic subset distributions in rats carrying the dunning R3327‐MAT‐LyLu prostatic adenocarcinoma
Author(s) -
Shaw Michael W.,
Rubenstein Marvin,
Dubin Alvin,
McKiel Charles F.,
Guinan Patrick D.
Publication year - 1987
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990110203
Subject(s) - cyclophosphamide , adenocarcinoma , cytotoxic t cell , chemotherapy , suppressor , immune system , monoclonal antibody , t cell , cancer research , cancer , medicine , immunology , biology , in vitro , antibody , biochemistry
The Dunning R3327 adenocarcinoma represents a model for studying prostate cancer in rats; early studies have indicated its utility for studying relationships between tumor growth, immunologic markers, and chemotherapy. Normal animals and those bearing the metastatic Dunning R3327 MAT‐LyLu tumor were treated with 10, 30, and 100 mg/kg doses of cyclophosphamide (CTX) and their spleens assayed for leukocytic subset distributions using monoclonal antibodies. Tumor‐bearing animals had significant reductions in helper T cell content as well as reduced helper/suppressor T cell ratios, compared to controls. These effects occurred rapidly following implantation and were not reversed by chemotherapy. When administered to both tumor‐ and non‐tumor‐bearing animals, CTX also depleted T cell populations. Despite reductions produced in all subsets, two administrations of CTX (30 mg/kg) were capable of retaining (in non‐tumor‐bearing animals) or restoring (in tumor‐bearing) normal helper/suppressor T cell ratios. Such studies aid in identifying therapeutically effective dosages of cytotoxic drugs that minimize their deleterious effects on the immune system.